<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 205498

                                    FORM 10-Q

(Mark One)

[X] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934.

For the quarterly period ended September 30, 1999
                               ------------------

                                       or

[ ] Transitional report pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transitional period from                       to
                                 ----------------------  ----------------------

Commission file number  0-29100
                      ---------

                        PREMIER RESEARCH WORLDWIDE, LTD.
             -----------------------------------------------------
             (Exact name of registrant as specified in its charter)

<TABLE>
<CAPTION>
<S>                                                                  <C>
                          Delaware                                                            22-3264604
-------------------------------------------------------------        --------------------------------------------------------------
       (State or other jurisdiction of incorporation                                (I.R.S. Employer Identification No.)
                      or organization)

                  30 South 17th Street
                    Philadelphia, PA                                                               19103
-------------------------------------------------------------        --------------------------------------------------------------
       (Address of principal executive offices)                                                  (Zip Code)

</TABLE>

                                  215-972-0420
              ----------------------------------------------------
              (Registrant's telephone number, including area code)


                                       N/A
--------------------------------------------------------------------------------
              (Former name, former address and formal fiscal year,
                          if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports, and (2) has been subject to such filing
requirements for the past 90 days. X  Yes    No
                                  ---    ---

Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.

The number of shares of Common Stock, $.01 par value, outstanding as of November
12, 1999, was 6,862,250.

<PAGE>


                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES

                                      INDEX
                                      -----
<TABLE>
<CAPTION>

                                                                                                                       Page
                                                                                                                       ----
<S>                                                                                                                  <C>
Part I.  Financial Information

             Item 1.       Financial Statements

                           Condensed consolidated balance sheets--September 30, 1999 (unaudited) and
                           December 31, 1998                                                                              3
                           Condensed consolidated statements of operations (unaudited)--Three Months
                           And Nine Months Ended September 30, 1999 and 1998                                              4

                           Condensed consolidated statements of cash flows (unaudited)--Nine Months
                           Ended September 30, 1999 and 1998                                                              5

                           Notes to condensed consolidated financial statements (unaudited)                             6-8

             Item 2.       Management's Discussion and Analysis of Financial Condition and Results of
                           Operations                                                                                  8-13

             Item 3.       Qualitative and Quantitative Disclosures about Market Risks.                                  13


Part II. Other Information 13
             Item 2.       Changes in Securities and Use of Proceeds                                                     14

             Item 6.       Exhibits and Reports on Form 8-K                                                              15

                           a.)      Exhibits


                           b.)      Reports on Form 8-K


Signatures                                                                                                               16
</TABLE>
                                       2




<PAGE>


                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                      (in thousands, except share amounts)
<TABLE>
<CAPTION>


                                                                                 September 30, 1999        December 31, 1998
                                                                                 ------------------        -----------------
                                                                                    (unaudited)
<S>                                                                                <C>                      <C>
ASSETS

Current assets:
   Cash and cash equivalents                                                             $ 12,893                   $ 10,822
   Short-term investments                                                                   4,604                      5,668
   Accounts receivable, net                                                                10,963                     10,423
   Prepaid expenses and other                                                               1,486                      2,176
   Deferred income taxes                                                                      159                        159
                                                                                         --------                   --------
         Total current assets                                                              30,105                     29,248

Property and equipment, net                                                                 4,408                      4,110
Goodwill, net                                                                               1,923                      2,160
Other assets                                                                                1,023                      1,023
Deferred income taxes                                                                       2,644                      3,631
                                                                                         --------                   --------
                                                                                         $ 40,103                   $ 40,172
                                                                                         ========                   ========


LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
   Accounts payable                                                                         1,520                   $  2,519
   Accrued expenses                                                                         3,273                      1,156
   Deferred revenues                                                                        4,583                      5,556
                                                                                         --------                   --------
         Total current liabilities                                                          9,376                      9,231
                                                                                         --------                   --------
Commitments and contingencies

Stockholders' equity:
    Preferred stock-$10 par value, 500,000 shares authorized,
               none issued and outstanding                                                      --                         --
    Common stock-$.01 par value, 15,000,000 shares authorized,
               7,322,530 and 7,217,520 shares issued                                            73                         72
    Additional paid-in capital                                                              37,298                     37,061
    Treasury stock, 499,800 and 177,800 shares at cost                                      (2,711)                      (779)
    Accumulated deficit                                                                     (3,933)                    (5,413)
                                                                                          --------                   --------
         Total stockholders' equity                                                         30,727                     30,941
                                                                                          --------                   --------
                                                                                          $ 40,103                   $ 40,172
                                                                                          ========                   ========
</TABLE>


         The accompanying notes are an integral part of these statements


                                       3

<PAGE>

                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                    (in thousands, except per share amounts)
<TABLE>
<CAPTION>

                                                         Three Months Ended                          Nine Months Ended
                                                            September 30,                              September 30,
                                                   ----------------------------             ----------------------------------
                                                        1999            1998                       1999               1998
                                                        ----            ----                       ----               ----
                                                            (unaudited)                                 (unaudited)

<S>                                                <C>               <C>                     <C>                  <C>
Revenues                                             $ 13,804        $  9,855                   $ 39,984             $ 27,443
Less-Reimbursed costs                                  (2,363)         (1,696)                    (8,026)              (4,440)
                                                     --------        --------                   --------             --------

Net revenues                                           11,441           8,159                     31,958               23,003
                                                     --------        --------                   --------             --------
Costs and expenses:
     Direct costs                                       4,343           3,360                     13,891                9,677
     Selling, general and administrative                5,638           4,251                     14,325               12,182
     Depreciation and amortization                        585             416                      1,658                1,146
                                                     --------        --------                   --------             --------
Total costs and expenses                               10,566           8,027                     29,874               23,005
                                                     --------        --------                   --------             --------
Income (loss) from operations                             875             132                      2,084                   (2)

Other income, net                                          97             216                        383                  727
                                                     --------        --------                   --------             --------
Income before income taxes                                972             348                      2,467                  725
Income tax provision                                      389             138                        987                  290
                                                     --------        --------                   --------             --------
Net income                                           $    583        $    210                   $  1,480             $    435
                                                     ========        ========                   ========             ========

Basic and diluted net income per share               $   0.08        $   0.03                   $   0.21             $   0.06
                                                     ========        ========                   ========             ========
</TABLE>





         The accompanying notes are an integral part of these statements

                                       4



<PAGE>



                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (in thousands)
<TABLE>
<CAPTION>
                                                                                             Nine Months Ended September 30,
                                                                                           ---------------------------------
                                                                                               1999                   1998
                                                                                               ----                   ----
                                                                                                       (unaudited)
<S>                                                                                        <C>                    <C>
Operating activities:
  Net income                                                                               $  1,480               $    435
  Adjustments to reconcile net income to net cash
          provided by (used in) operating activities:
                Depreciation and amortization                                                 1,658                  1,146
                Provision for doubtful accounts                                                 206                     --
                Deferred income taxes                                                           987                    290
                Changes in assets and liabilities:
                    Accounts receivable                                                        (746)                (3,105)
                    Prepaid expenses and other                                                  690                   (510)
                    Accounts payable                                                           (999)                  (673)
                    Accrued expenses                                                          2,117                    302
                    Deferred revenues                                                          (973)                 1,558
                                                                                           --------               --------
                         Net cash provided by (used in) operating activities                  4,420                   (557)
                                                                                           --------               --------

Investing activities:
     Purchases of property and equipment                                                     (1,719)                (1,756)
     America's Doctor investment                                                                 --                 (1,000)
     Proceeds from sales of short-term investments                                            1,064                  9,462
                                                                                           --------               --------
                         Net cash provided by (used in) investing activities                   (655)                 6,706
                                                                                           --------               --------

Financing activities:
     Repurchase of common stock for treasury                                                 (1,932)                  (540)
     Net proceeds from exercise of stock options                                                238                    552
                                                                                           --------               --------
                         Net cash provided by (used in) financing activities                 (1,694)                    12
                                                                                           --------               --------
Net increase in cash and cash equivalents                                                     2,071                  6,161
Cash and cash equivalents, beginning of period                                               10,822                  4,679
                                                                                           --------               --------

Cash and cash equivalents, end of period                                                   $ 12,893               $ 10,840
                                                                                           ========               ========
</TABLE>



         The accompanying notes are an integral part of these statements

                                       5


<PAGE>



                PREMIER RESEARCH WORLDWIDE, LTD. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (Unaudited)

Note 1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-Q and Article 10 of
Regulation S-X. Accordingly, they do not include all the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring adjustments) considered necessary for fair presentation have
been included. Operating results for the periods ended September 30, 1999, are
not necessarily indicative of the results that may be expected for the year
ending December 31, 1999. Further information on potential factors that could
affect the Company's financial results can be found in the Company's S-1
Registration Statement and its Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission.

Note 2. Net Income per Share

The Company follows SFAS No. 128 "Earnings per Share". This statement requires
the presentation of basic and diluted earnings per share. Basic net income per
share is computed by dividing net income by the weighted average number of
shares of common stock outstanding during the year. Diluted net income per share
is computed by dividing net income by the weighted average number of shares of
common stock outstanding during the year, adjusted for the dilutive effect of
common stock equivalents, which consist primarily of stock options, using the
treasury stock method.

The table below sets forth the reconciliation of the numerators and denominators
of the basic and diluted net income per share computations.

Three Months Ended September 30,
--------------------------------
<TABLE>
<CAPTION>

                                                                                                        Per
                                                                      Net                              Share
1999                                                                Income          Shares             Amount
----                                                                ------          ------             ------

<S>                                                               <C>             <C>                  <C>
Basic........................................................     $ 583,000       7,011,000            $  0.08
Effect of dilutive shares...................................             --          74,000                 --
                                                                  ---------       ---------            -------
Diluted......................................................     $ 583,000       7,085,000            $  0.08
                                                                  =========       =========            =======

1998
----
Basic........................................................     $ 210,000       7,106,000            $  0.03
Effect of dilutive shares...................................             --          79,000                 --
                                                                  ---------       ---------            -------
Diluted......................................................     $ 210,000       7,185,000            $  0.03
                                                                  =========       =========            =======
</TABLE>

Options to purchase 213,029 and 652,132 shares of common stock were outstanding
at September 30, 1999 and 1998, respectively but were not included in the
computation of diluted net income per share for the three months ended September
30, 1999 and 1998 because the option exercise prices were greater than the
average market price of the Company's common stock during the period.


                                       6


<PAGE>



Nine Months Ended September 30,
-------------------------------
<TABLE>
<CAPTION>

                                                                                                        Per
                                                                      Net                              Share
1999                                                                Income          Shares             Amount
----                                                                ------          ------             ------

<S>                                                               <C>             <C>                  <C>
Basic........................................................   $ 1,480,000       7,057,000            $  0.21
Effect of dilutive shares...................................             --          94,000                 --
                                                                -----------       ---------            -------
Diluted......................................................   $ 1,480,000       7,151,000            $  0.21
                                                                ===========       =========            =======

1998
----

Basic........................................................   $   435,000       7,121,000            $  0.06
Effect of dilutive shares...................................             --          96,000                 --
                                                                -----------       ---------            -------
Diluted......................................................   $   435,000       7,217,000            $  0.06
                                                                ===========       =========            =======
</TABLE>

Options to purchase 239,275 and 634,951 shares of common stock were outstanding
at September 30, 1999 and 1998, respectively but were not included in the
computation of diluted net income per share for the nine months ended September
30, 1999 and 1998 because the option exercise prices were greater than the
average market price of the Company's common stock during the period.

Note 3. Comprehensive Income

The Company follows SFAS No. 130, "Reporting Comprehensive Income." The
Company's comprehensive income includes net income and unrealized gains and
losses from foreign currency translation and short-term investments. These
unrealized gains and losses were immaterial as of September 30, 1999 and 1998.

Note 4 Operating Segments

In June 1997, SFAS No. 131, "Disclosure about Segments of an Enterprise and
Related Information," was issued, effective for fiscal years ending after
December 15, 1998. The Company adopted this statement for the year ended
December 31, 1998. The Company's reportable segments are strategic business
units that offer different products and services to a common client base.

The Company's products and services are provided through two business segments,
both in the United States and internationally: Clinical Operations, which
includes centralized diagnostic testing services, clinical trial management
services and clinical data management services; and Technology Operations, which
includes clinical trial and data management software, support and consulting
services. The Company's discontinued Phase I Clinical Research Unit and Clinical
Laboratory operations and income and expense not allocated to reportable
segments are reported as Other.

The Company evaluates performance based on the net revenues and operating
earnings performance of the respective business segments.


                                       7

<PAGE>



Segment information is as follows:
<TABLE>
<CAPTION>


                                                                      Three months ended September 30,1999
                                                       -------------------------------------------------------------------
                                                         Clinical
                                                       Operations         Technology               Other           Total
                                                       ----------         ----------               -----           -----
<S>                                                    <C>                <C>                 <C>              <C>
Net revenues from external customers                   $  6,915,000       $  4,439,000        $    87,000      $11,441,000
Income (loss) from operations                              (772,000)         1,799,000           (152,000)         875,000
Identifiable assets                                      14,763,000          3,912,000         21,428,000       40,103,000

                                                                     Three months ended September 30, 1998
                                                       -------------------------------------------------------------------
                                                         Clinical
                                                       Operations         Technology               Other           Total
                                                       ----------         ----------               -----           -----
Net revenues from external customers                     $5,146,000         $2,611,000           $402,000       $8,159,000
Income (loss) from operations                              (497,000)           684,000            (55,000)         132,000
Identifiable assets                                      10,695,000          3,494,000         24,128,000       38,317,000

                                                                       Nine months ended September 30,1999
                                                       -------------------------------------------------------------------
                                                         Clinical
                                                       Operations         Technology               Other           Total
                                                       ----------         ----------               -----           -----
Net revenues from external customers                    $23,055,000         $8,324,000           $579,000      $31,958,000
Income (loss) from operations                               300,000          2,240,000           (456,000)       2,084,000
Identifiable assets                                      14,763,000          3,912,000         21,428,000       40,103,000

                                                                      Nine months ended September 30, 1998
                                                       -------------------------------------------------------------------
                                                         Clinical
                                                       Operations         Technology           Other               Total
                                                       ----------         ----------           -----               -----
Net revenues from external customers                    $13,955,000         $7,592,000         $1,456,000      $23,003,000
Income (loss) from operations                            (1,639,000)         1,368,000            269,000           (2,000)
Identifiable assets                                      10,695,000          3,494,000         24,128,000       38,317,000

</TABLE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
        of Operations

Overview

The Company is a clinical research organization providing a broad range of
integrated product development services on a global basis to its clients in the
pharmaceutical, biotechnology and medical device industries. The Company's
products and services are provided, both in the United States and
internationally, through two business segments: Clinical Operations, which
includes centralized diagnostic testing services, clinical trial management
services and clinical data management services; and Technology Operations, which
includes the development, marketing and support of clinical trial and data
management software, support and consulting services. The Company had operated a
Phase I Clinical Research Unit, which was closed in the first quarter of 1998.

         The Company's centralized diagnostic testing services are on a
fee-for-service basis and contracts generally have terms of one month to two
years. A portion of the Company's fee frequently is paid upon contract execution
as a non-refundable up-front payment, with the remaining amounts billed monthly.
Clinical trial and data management services are generally fixed priced
contracts, with certain variable components, and range in duration from a few
months to two years. A portion of the Company's fee frequently is paid upon
contract execution as a non-refundable up-front payment, with the balance billed
in accordance with the contract terms. The Company's contracts generally may be
terminated with or without cause on 30 to 90 days notice. Clients terminate or
delay contracts for a variety of reasons, including, among others, the failure
of the product(s) being tested to satisfy safety or efficacy requirements;
unexpected or undesired clinical results of the product; the client's decision
to forego a particular study; insufficient patient enrollment or investigator
recruitment; and production problems resulting in shortages of required
supplies. Revenues from clinical trial software and services are derived
primarily from software license fees, software maintenance and support and
consulting services.

                                       8
<PAGE>


         Revenues from centralized diagnostic testing services are recognized as
the services are performed. Revenues from clinical trial and data management
services are generally recognized on a percentage of completion basis as work is
performed. The Company regularly subcontracts with third-party investigators in
connection with clinical trials and with other third-party providers for
specialized services. These and other reimbursable costs are paid by the Company
and reimbursed by clients and, in accordance with industry practice, are
included in revenues. Since reimbursed costs may vary significantly from
contract to contract and are not meaningful for analyzing trends in revenues,
they are included in gross revenues but excluded from net revenues.

              Revenues from technology software licenses are recognized upon
shipment of the software and related documentation when collectibility is deemed
probable and the license fee is deemed fixed and determinable. Revenues from
software maintenance and continuing support contracts are recognized on a
straight-line basis over the period in which the software maintenance and
continuing support is provided, generally twelve months. Revenues from
consulting and training services are recognized when the services are performed.

Results of Operations

Three months ended September 30, 1999 compared to three months ended September
30, 1998

Net revenues for the three months ended September 30, 1999, increased $3,282,000
or 40.2% to $11,441,000 compared to $8,159,000 for the three months ended
September 30, 1998.

The Company's net revenues from its Clinical Operations increased $ 1,768,000 or
34.3% to $6,915,000 for the period ended September 30, 1999 compared to
$5,146,000 for the same period in 1998. The increase in net revenues was the
result of the Company's strong performance in centralized diagnostic testing
services, which increased $1,558,000 or 78.0% to $3,555,000 in the 1999 period
from $1,996,000 in the 1998 period. In addition, the Company's clinical trial
and data management services net revenues increased $210,000 or 6.7% to
$3,360,000 for the three months ended September 30, 1999 from $3,150,000 for the
three months ended September 30, 1998. Overall, the increase in net revenues for
Clinical Operations resulted from revenues recognized from the Company's
contract backlog and new clinical contracts signed during 1999.

The Company has decided to phase out its clinical laboratory operations, which
primarily provided blood sample testing in conjunction with clinical trials.
Contractual client obligations for these services will be met through
subcontracting agreements with comparable laboratories, beginning in the third
quarter of 1999. During the three months ended September 30, 1999, net revenues
from clinical laboratory operations were $87,000 compared to $347,000 for the
three months ended September 30, 1998.

Net revenues for Technology Operations increased $1,828,000 or 70.0% to
$4,439,000 for the three months ended September 30, 1999 from $2,611,000 for the
three months ended September 30, 1998. During the third quarter of 1999, the
Company signed a five-year agreement to provide software and consulting services
to link up to four hundred investigational sites in a worldwide oncology trial.
The increase in net revenues was due primarily to the recognition of the first
portion of the revenue from this contract. Included in the net revenues of
Technology Operations for the three months ended June 30, 1999 was $575,000 in
consulting revenues relating to the Company's consulting contract with
AmericasDoctor.com, Inc.

During the third quarter of 1998, the Company recorded net revenues of $55,000
from its Phase I unit, which was closed during the first quarter of 1998.

Direct costs for the three months ended September 30, 1999 increased $983,000 or
29.3% to $4,343,000 from $3,360,000 for the three months ended September 30,
1999. The increase in direct costs is due to increased staffing and
subcontracting costs to support client contract requirements and to accommodate
projected future net revenues. Direct costs, as a percentage of net revenues,
for the three months ended September 30, 1999 were 38.0% compared with 41.2% in
1998. The decrease in direct costs as a percentage of revenues was due primarily
to the Company's ability to leverage the fixed portion of its direct costs
against an increased revenue base.

                                       9
<PAGE>



Selling, general and administrative expenses increased $1,387,000 or 32.6% to
$5,638,000 for the three months ended September 30, 1999 from $4,251,000 for the
three months ended September 30, 1998. The increase in selling, general and
administrative expenses is due to increased personnel and personnel related
costs, performance-based incentive compensation programs established in 1999 and
direct selling expenses related to Technology license revenues recognized in the
quarter. As a percentage of net revenues, selling, general and administrative
expenses were 49.3% for the third quarter of 1999 compared to 52.1% for the
third quarter of 1998. The decline in the percentage was due primarily to the
Company's ability to leverage the fixed portion of its selling, general and
administrative expenses against an increased revenue base.

Depreciation and amortization expense increased to $585,000 in the third quarter
of 1999 from $416,000 in the comparable 1998 quarter. The increase was due to
increased depreciation expense resulting from additional capital spending to
support the growth in net revenues.

Other income, which consists primarily of interest earned on the Company's cash,
cash equivalents and short-term investments, decreased to $97,000 from $216,000
for the three months ended September 30, 1999 and 1998, respectively. The
decrease is due to lower cash and short-term investment balances in 1999 as a
result of the Company's use of cash to support working capital, capital
expenditure needs and the share repurchase program in 1999.

The Company's effective tax rate was 40.0% for the three months ended September
30, 1999 and 1998.

Nine months ended September 30, 1999 compared to nine months ended September 30,
1998

Net revenues for the nine months ended September 30, 1999, increased $8,955,000
or 38.9% to $31,958,000 compared to $23,003,000 for the nine months ended
September 30, 1998.

The Company continued to experience a strong increase in net revenues in its
Clinical Operations, which increased $9,100,000 or 65.2% to $23,055,000 for the
period ended September 30, 1999 compared to $13,955,000 for the same period in
1998. The increase in net revenues was the result of the Company's strong
performance in centralized diagnostic testing services, which increased
$4,406,000 or 78.1% to $10,045,000 in the 1999 period from $5,639,000 in the
1998 period. In addition, the Company's clinical trial and data management
services net revenues increased $4,694,000 or 56.4% to $13,010,000 for the nine
months ended September 30, 1999 from $8,316,000 for the nine months ended
September 30, 1998. Overall, the increase in net revenues for Clinical
Operations resulted from revenues recognized from the Company's contract backlog
and new clinical contracts signed during the nine months ended September 30,
1999.

The Company has decided to phase out its clinical laboratory operations, which
primarily provides blood sample testing in conjunction with clinical trials.
Contractual client obligations for these services will be met through
subcontracting agreements with comparable laboratories, beginning in the third
quarter of 1999. During the nine months ended September 30, 1999, net revenues
from clinical laboratory operations were $579,000 compared to $1,267,000 for the
nine months ended September 30, 1998.

Net revenues for Technology Operations increased $732,000 or 9.6% to $8,324,000
for the nine months ended September 30, 1999 from $7,592,000 for the nine months
ended September 30, 1998. During the third quarter of 1999, the Company signed a
significant, five-year agreement to provide software and consulting services to
link up to four hundred investigational sites in a worldwide oncology trial. The
increase in net revenues was due primarily to the recognition of the first
portion of the revenue from this contract. Included in the net revenues for
Technology Operations for the nine months ended September 30, 1999 was
$1,725,000 in consulting revenues relating to the Company's consulting contract
with AmericasDoctor.com, Inc.

During the nine months ended September 30, 1998, the Company recorded net
revenues of $189,000 from its Phase I unit, which was closed during the first
quarter of 1998.

Direct costs for the nine months ended September 30, 1999 increased $4,214,000
or 43.5% to $13,891,000 from $9,677,000 for the nine months ended September 30,
1999. The increase in direct costs is due to increased staffing and
subcontracting costs to support client contract requirements and to accommodate
projected future net revenues. Direct costs, as a percentage of net revenues,
for the nine months ended September 30, 1999 were 43.5% compared to 42.1% for
the same period in 1998. The increase in direct costs as a percentage of net
revenues is due to the increase in staff and subcontracting costs and to the
mix of revenues as Clinical Operations net revenues have a higher direct cost
ratio than Technology Operations net revenues.

                                       10
<PAGE>



Selling, general and administrative expenses increased $2,143,000 or 17.6% to
$14,325,000 for the nine months ended September 30, 1999 from $12,182,000 for
the nine months ended September 30, 1998. The increase in selling, general and
administrative expenses is due to increased personnel related, performance-based
incentive compensation programs established in 1999, direct selling expenses
related to Technology license revenues recognized in the third quarter and other
expenses incurred in the nine months ended September 30, 1999 including $250,000
of closedown costs for the clinical laboratory. As a percentage of net revenues,
selling, general and administrative expenses were 44.8% for the nine months
ended September 30, 1999 compared to 53.0% for the nine months ended September
30, 1998. The decline in the percentage was due primarily to the Company's
ability to leverage the fixed portion of its selling, general and administrative
expenses against an increased revenue base.

Depreciation and amortization expense increased to $1,658,000 for the nine
months ended September 30, 1999 from $1,146,000 in the comparable 1998 period.
The increase was due to increased depreciation expense resulting from additional
capital spending to support the growth in net revenues.

Other income, which consists primarily of interest earned on the Company's cash,
cash equivalents and short-term investments, decreased to $383,000 from $727,000
for the nine months ended September 30, 1999 and 1998, respectively. The
decrease is due to lower cash and short-term investment balances in 1999 as a
result of the Company's use of cash to support working capital and capital
expenditure needs and the share repurchase program in 1999.

The Company's effective tax rate was 40.0% for the six months ended June 30,
1999 and 1998.


Liquidity and Capital Resources

For the nine months ended September 30, 1999, the Company generated cash from
operations of $4,420,000 compared to cash used in operations of $557,000 for the
nine months ended September 30, 1998. The year-to-year change was primarily the
result of increased income before depreciation and amortization, increased
accrued expenses and improved receivable collection partially offset by reduced
accounts payable and deferred revenues.

At September 30, 1999, the Company had $12,893,000 of cash and cash equivalents
and $4,604,000 invested in short-term marketable securities. For the nine months
ended September 30, 1999, the Company sold, upon maturity, $1,064,000 of
short-term investments and re-invested the proceeds in investments with
maturities of ninety days or less. The Company generally places its investments
in A1P1 rated commercial bonds and paper, municipal securities and certificates
of deposit with maturities of less than one year.

During the nine months ended September 30, 1999, the Company purchased
$1,719,000 of equipment compared to $1,756,000 during the nine months ended
September 30, 1998. The equipment purchases in 1999 reflect the additional
capital equipment needed to support the growth of the Company.

During the nine months ended September 30, 1999, the Company received $238,000
in cash from the exercise of 105,010 employee stock options.

The Company has renewed through June 30, 2000, its bank line of credit that
provides for borrowings up to $3,000,000 at an interest rate of prime minus 35
basis points. The line of credit agreement includes certain covenants, the most
restrictive of which limit future indebtedness and require compliance with a
liabilities-to-tangible net worth ratio. To date, the Company has not borrowed
any amounts under its line of credit.

During the nine months ended September 30, 1999, the Company used $1,932,000 to
repurchase 322,000 shares of the Company's common stock at a price of $6 per
share. The Company's share repurchase program is now complete, having
repurchased 499,800 shares of the 500,000 authorized by the Board of Directors
on July 20, 1998. In total, the Company used $2,711,000 to repurchase 499,800
shares at an average price of $5.42 per share.

The Company expects that existing cash and cash equivalents, short-term
investments, cash flows from operations and borrowings under its line of credit
will be sufficient to meet its foreseeable cash needs for at least the next
year. However, there may be acquisition and other growth opportunities that
require additional external financing and the Company may from time to time seek
to obtain additional funds from the public or private issuances of equity or
debt securities. There can be no assurance that such financings will be
available or available on terms acceptable to the Company.

                                       11
<PAGE>



Year 2000

The Company is aware of the issues and problems associated with the Year 2000
date change. The Company has been addressing company-wide data processing and
infrastructure issues since 1995. Premier Research had undertaken a Year 2000
Compliance Plan that was completed by September 30, 1999. In addition, the
Company had all clinical systems Year 2000 compliant by July 31, 1999. The
purpose of this plan is to assure that Premier Research, as a corporate entity,
has assessed and taken appropriate actions necessary to become compliant with
any issues regarding Year 2000 requirements. The problems surrounding Year 2000
compliance are of extreme concern to the Company, since Premier Research is a
clinical research organization providing diagnostic testing and clinical
research services to the pharmaceutical industry, as well as a developer of
clinical database management software. The Company produces and delivers
information that is date sensitive, especially in deriving date and time
calculations; Premier Research currently can provide to its clients, date
formats that contain century markers or 4-digit year fields for any of its
clinical and diagnostic information.

The Company's strategy to address Year 2000 compliance is to replace potentially
non-compliant software and hardware with new compliant systems or updated Year
2000 compliant versions. The inventory and assessment phases of the Year 2000
plan have primarily been completed for its hardware and software systems. The
Company has begun its remediation phase of the plan through the replacement and
updating of systems.

As of today all of the Company's information technology infrastructure has been
assessed and have been found free from any Year 2000 issues. Those that have
shown not to be in compliance are currently being evaluated and renovated for
compliance. If a system can not be made compliant to the requirements, the
system will be replaced with one that is compliant.

The Company is also assessing its facilities worldwide that it leases or owns,
and plans to complete its deployment of applicable contingency plans by December
1, 1999.

The Company is also assessing and surveying its suppliers of third party
products and services. Based upon information received from such parties, the
Company believes that most of its suppliers are developing, assessing and
remediating any issues associated with their Year 2000 plans. The Company cannot
at this time fully assess the status of its suppliers until they have completed
their own efforts. It will review the readiness of the suppliers on an on-going
basis throughout the remainder of the year and will implement specific actions
to rectify potential problems in its supply chain.

As with any other company in its industry or any business in general, the
Company is exposed to risks associated with failures in the private and public
sector to become Year 2000 compliant. These risks include the possibility that
public infrastructure systems, such as electricity, water, natural gas or
telecommunications may fail in this country and other countries in the world
that the Company does business. In addition, there are those risks that the
internal systems of the Company's suppliers, service providers and customers
will fail. The Company also relies considerably on travel and could be adversely
affected, if air and train travel is disrupted by issues related to the Year
2000.

The Company also relies heavily on the healthcare industry. This industry and
its related clinical investigational sites may not have focused their efforts on
the Year 2000 issue to the same degree. Thus the Company has an increased risk
that its investigational sites, necessary for the conduct of clinical trials,
will be unable to provide timely answers and data that it needs to perform
services on time to its contractual clients. Also, the failure of the Company's
customers to address the Year 2000 issue could negatively impact on their
ability to use the Company's services. While contingency plans will be developed
to address these risks, the Company cannot assure that those plans will
sufficiently protect the Company from the effects of those risks. Any
disruptions from the realization of any of these risks could adversely affect
the Company's ability to perform its services.

The Company estimates that the costs associated with its Year 2000 program will
be approximately $ 0.5 million, including costs already incurred. Total Year
2000 costs of approximately $0.3 million have been incurred by the Company
through September 30, 1999. The estimates of cost, timing and impact of
addressing the Year 2000 issue are based on numerous assumptions of future
events, including the continued availability of certain resources, the ability
of the Company to meet its deadlines and the cooperation of third parties.
However, there can be no guarantee that the assumptions will be correct and that
these estimates will be achieved. Actual results could differ significantly from
those expected by the Company.

                                       12
<PAGE>



Inflation

The Company believes the effects of inflation generally do not have a material
adverse effect on its results of operations or financial condition.

Cautionary Statement for Forward-Looking Information.

Statements included in Management's Discussion and Analysis of Financial
Condition and Results of Operations set forth above may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties such as competitive factors, technology development, market demand
and the Company's ability to obtain new contracts and accurately estimate net
revenues due to variability in size, scope and duration of projects, and
internal issues of the sponsoring client. Further information on potential
factors that could affect the Company's financial results can be found in the
Company's S-1 Registration Statement and its Reports on Form 10-K and 10-Q filed
with the Securities and Exchange Commission.

Item 3. Qualitative and Quantitative Disclosures About Market Risk

The Company's primary financial market risks include fluctuations in interest
rates and currency exchange rates.

There have been no significant changes since December 31, 1998.




                                       13



<PAGE>



Part II. Other Information

Item 2. Changes in Securities and Use of Proceeds
<TABLE>
<CAPTION>
<S>     <C>                                  <C>                                  <C>



(1)    Effective Date of Securities Act Registration Statement:        February 3, 1997
       registration No.:   333-17001

(2)    Offering Date:      February 4, 1997

(3)      Not Applicable

(4)     (i) The offering terminated after all shares registered were sold

       (ii) Managing Underwriters:  Montgomery Securities
                                    Furman Selz
                                    Genesis Merchant Group

      (iii) Class of Securities Registered: Common Stock

       (iv)                                    Account of Company             Account of Selling Shareholder
                                               ------------------             ------------------------------
            Amount Registered                  2,206,250 common stock         956,250 common stock

            Aggregate price of
            Amount Registered                  $37,506,250                    $16,256,250

            Amount Sold                          2,206,250                        956,250

            Aggregate Offering
            Price of Amount Sold               $37,506,250                     16,256,250

       (v)  Expenses of offering for account of the Company:
            Underwriting Discount and Commission                               $2,625,437
            Other expenses                                                       $698,813
            Total Expenses                                                     $3,324,250

            (A)   There were no direct or indirect payments to directors,
                  officers, general partners of the issuer or their associates;
                  to persons owning ten (10) percent or more of common stock of
                  the Company; or affiliates of the Company.

            (B) All of the above payments were direct or indirect payments to others not
                described in clause (A).


      (vi)  Net Offering Proceeds to the Company:                             $34,182,000

     (vii)  Use of Proceeds as of September 30, 1999:
            Net cash paid for business acquisition:                             8,655,000
            Net cash paid for minority equity investment                        1,000,000
            Common stock re-purchase                                            2,711,000
            Purchase of Equipment:                                              6,579,000
            Working Capital:                                                   (2,260,000)
            Temporary Investments (consisting of short-term,
            Investment-grade securities):                                       4,604,000

            All of the above payments were to others not described in item (v)(A) above.

    (viii) The use of proceeds is consistent with the Prospectus

</TABLE>
                                       14

<PAGE>



Item 6. Exhibits and Reports on Form 8-K

        a.) Exhibits

            10.25 Registration Rights Agreement dated August 27, 1999.
                  Incorporated by reference to Exhibit 10.1, filed in connection
                  with the Company's Form 8-K dated August 27, 1999.

            10.26 Put Option Agreement dated August 27, 1999. Incorporated by
                  reference to Exhibit 10.1, filed in connection with the
                  Company's Form 8-K dated August 27, 1999.

            10.27 Employment Agreement with Joel Morganroth, M.D., filed
                  herewith. *

            10.28 Management Consulting Agreement with Joel Morganroth, M.D.,
                  filed herewith. *

            10.29 Employment Agreement with Joseph Esposito, filed herewith. *

            10.30 Employment Agreement with John R. Bauer, filed herewith. *

            10.31 Amendment No. 1 to Premier Research Worldwide 1996 Stock
                  Option Plan (Incorporated by reference to Exhibit 4.2 to the
                  Registration Statement on Form S-8, File No. 333-80121). *

            27.0  Financial Data Schedule

            * Management contract or compensatory plan or arrangement.


        b.) Reports on Form 8-K

            On September 9, 1999 the Registrant filed a Report on Form 8-K dated
            August 27, 1999, reporting on a change in control.


                                       15


<PAGE>



                                   Signatures


              Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.



                                           PREMIER RESEARCH WORLDWIDE, LTD.
                                                     (Registrant)

Date:  November 15, 1999                   By: /s/ Joel Morganroth
                                              ---------------------------------
                                                   Joel Morganroth, MD
                                                   Chairman and Chief
                                                   Executive Officer



Date:  November 15, 1999                   By: /s/ John R. Bauer
                                              ----------------------------------
                                                   John R. Bauer
                                                   Chief Financial Officer
                                                   (Principal Financial an
                                                   Accounting Officer)

                                       16